The Faculty of Medicine, Hebrew University of Jerusalem, Israel; Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
The Faculty of Medicine, Hebrew University of Jerusalem, Israel; Department of Clinical Microbiology and Infectious Diseases, Hadassah Hebrew University Medical Center, Jerusalem, Israel.
Clin Microbiol Infect. 2022 May;28(5):735.e1-735.e3. doi: 10.1016/j.cmi.2022.01.019. Epub 2022 Feb 7.
In August 2021, 6 months after mass vaccination of the Israeli population with the two-dose BNT162b2 mRNA vaccine, a surge of coronavirus disease 2019 infections, mostly from the delta variant, appeared also among the vaccinated. In response, the Israeli Ministry of Health initiated a booster (third dose) vaccination program. We assessed the protective effect of the third dose among health care workers (HCWs).
Infections with severe acute respiratory syndrome coronavirus 2 are monitored systematically among HCWs at the Hadassah tertiary care medical centre in Jerusalem, Israel. In this cohort, we included breakthrough infections, defined as those occurring >180 days since the second vaccine dose. The follow-up period lasted 120 days. We compared infection rates between HCWs who received the booster dose and those who received only the two-dose regimen.
The rate of breakthrough infections among HCWs who received only the two-dose regimen was 21.4% (85 of 398). The rate in the boosted group was 0.7% (35/4973; relative risk 30, 95% CI 20-50). Those results were seen in all age groups.
The significantly lower rate of breakthrough infections in boosted HCWs indicates substantial protection by a third vaccine dose.
2021 年 8 月,在以色列民众大规模接种两剂 BNT162b2 mRNA 疫苗 6 个月后,新型冠状病毒疾病 2019 感染人数也在接种人群中出现激增,主要来自德尔塔变异株。作为回应,以色列卫生部启动了加强针(第三剂)接种计划。我们评估了第三剂在医护人员(HCWs)中的保护作用。
在以色列耶路撒冷哈达萨三级保健医疗中心,对 HCWs 中严重急性呼吸系统综合征冠状病毒 2 的感染进行系统监测。在这个队列中,我们纳入了突破性感染,定义为距第二剂疫苗接种后 >180 天发生的感染。随访期持续 120 天。我们比较了接受加强针剂量和仅接受两剂方案的 HCWs 之间的感染率。
仅接受两剂方案的 HCWs 中突破性感染的发生率为 21.4%(398 例中的 85 例)。在加强组中,这一比例为 0.7%(35/4973;相对风险 30,95%CI 20-50)。这些结果在所有年龄组中均可见。
加强针 HCWs 中突破性感染的发生率显著降低,表明第三剂疫苗具有实质性的保护作用。